75 related articles for article (PubMed ID: 19800994)
1. Comparison of the anti-tumor activity of native, secreted, and membrane-bound LIGHT in mouse tumor models.
Morishige T; Yoshioka Y; Tanabe A; Yao X; Mizuguchi H; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Int Immunopharmacol; 2010 Jan; 10(1):26-33. PubMed ID: 19800994
[TBL] [Abstract][Full Text] [Related]
2. Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation.
Zhang J; Wang Q; Zhao D; Cao X
Cytotherapy; 2007; 9(4):386-96. PubMed ID: 17573614
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
4. LIGHT protein suppresses tumor growth by augmentation of immune response.
Morishige T; Yoshioka Y; Inakura H; Tanabe A; Watanabe H; Yao X; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Immunol Lett; 2009 Dec; 127(1):33-8. PubMed ID: 19716382
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X
Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476
[TBL] [Abstract][Full Text] [Related]
6. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor.
Kanagawa N; Gao JQ; Motomura Y; Yanagawa T; Mukai Y; Yoshioka Y; Okada N; Nakagawa S
Biochem Biophys Res Commun; 2008 Aug; 372(4):821-5. PubMed ID: 18519033
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo.
Li Q; Li L; Shi W; Jiang X; Xu Y; Gong F; Zhou M; Edwards CK; Li Z
Cancer Immunol Immunother; 2006 Dec; 55(12):1470-9. PubMed ID: 16555058
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells.
Luo X; Yu Y; Liang A; Xie Y; Liu S; Guo J; Wang W; Qi R; An H; Zhang M; Xu H; Guo Z; Cao X
Cell Mol Immunol; 2004 Jun; 1(3):199-204. PubMed ID: 16219168
[TBL] [Abstract][Full Text] [Related]
9. An investigation of adverse effects caused by the injection of high-dose TNFalpha-expressing adenovirus vector into established murine melanoma.
Okada Y; Okada N; Mizuguchi H; Hayakawa T; Mayumi T; Mizuno N
Gene Ther; 2003 Apr; 10(8):700-5. PubMed ID: 12692598
[TBL] [Abstract][Full Text] [Related]
10. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L.
Calmels B; Paul S; Futin N; Ledoux C; Stoeckel F; Acres B
Cancer Gene Ther; 2005 Feb; 12(2):198-205. PubMed ID: 15472713
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus-mediated local delivery of LIGHT suppresses tumorigenesis in a murine cervical cancer model.
Maitituoheti M; Li Y; Wang W; Wang W; Han L; Yang R; Wang T; Wu Z; Ma D; Wang S
J Immunother; 2011 Oct; 34(8):581-7. PubMed ID: 21904218
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
13. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism.
Steitz J; Brück J; Knop J; Tüting T
Gene Ther; 2001 Aug; 8(16):1255-63. PubMed ID: 11509959
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
[TBL] [Abstract][Full Text] [Related]
17. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
18. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
19. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
20. LIGHT is dispensable for CD4+ and CD8+ T cell and antibody responses to influenza A virus in mice.
Sedgmen BJ; Dawicki W; Gommerman JL; Pfeffer K; Watts TH
Int Immunol; 2006 May; 18(5):797-806. PubMed ID: 16569673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
